Minerva Neurosciences, Inc. (NERV), a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system diseases, reported fourth-quarter financial results. It posted an adjusted loss of $0.64 per share for the quarter. The company did not report revenue as it does not have marketable products.
The company’s lead product candidate is roluperidone, which is being developed for the treatment of negative symptoms in patients with schizophrenia. Minerva continues to focus on advancing its pipeline of therapies targeting neurological and psychiatric disorders.
The Cambridge, Massachusetts-based company trades on the NASDAQ under the ticker symbol NERV.
This article was generated using AlphaStreet’s proprietary financial analysis technology and reviewed by our editorial team.